SAN CARLOS, CA -- (Marketwired) -- 11/23/16 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology (TIL), today announced that its President and Chief Executive Officer, Dr. Maria Fardis, and Chief Financial Officer, Greg Schiffman, will participate in a fireside chat at the upcoming 28th Annual Piper Jaffray Healthcare Conference on Wednesday, November 30, 2016 at 2:30 p.m. E.T. in New York, NY.
A live webcast of the presentation will be available by visiting the Investors section of Lion Biotechnologies' website at http://ir.lbio.com/. A replay of the webcast will be archived on Lion Biotechnologies' website for 30 days following the presentation.
About Lion Biotechnologies, Inc.
Lion Biotechnologies, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) for the treatment of patients with refractory metastatic melanoma. TIL therapy is also being evaluated in clinical trials at the National Cancer Institute and Moffitt Cancer Center. For more information, please visit http://www.lionbio.com.
Investor Contact:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah@sternir.com
Media Contact:
Alex Ferrara
inVentivHealth Public Relations
212-849-9487
Alexandra.Ferrara@inventivhealth.com
Source: Lion Biotechnologies, Inc.
Released November 23, 2016